## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)  1. Name and Address of Reporting Person* ROSENWALD LINDSAY A MD				2. Issuer Name and Ticker or Trading Symbol Checkpoint Therapeutics, Inc. [CKPT]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) (First) (Middle) 2 GANSEVOORT STREET, 9TH FLOOR				3. Date of Earliest Transaction (Month/Day/Year) 06/10/2021								Office	r (give title beld	ow)(	ther (specify b	elow)
(Street) NEW YORK, NY 10014				4. If Amendment, Date Original Filed(Month/Day/Year)						-	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person					
(City) (State) (Zip)				Table I - Non-Derivative Securities Acqui						Acqui	uired, Disposed of, or Beneficially Owned					
(Instr. 3)		2. Transaction Date (Month/Day/Year)		Date, if	Code (Instr. 8)		4. Securities Acqui (A) or Disposed of (Instr. 3, 4 and 5)		of (D)	Beneficia Reported	ally Owned Following d Transaction(s)		Form:	7. Nature of Indirect Beneficial		
				(Month/Da	y/Y ear		Code	V	Amount	(A) or (D)	Price	(Instr. 3 and 4)			Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)
COMMON STOCK 06/10/2021		06/10/2021			A			16,502 (1)	A	\$ 0	278,782 <sup>(2)</sup>			D		
			Table II - D				quired	l, Dis	posed of	, or Ben	eficiall		OMB con	trol number	•	
	2. Conversion or Exercise Price of Derivative Security	*****	3A. Deemed Execution Date	4. Transac Code	SS (Control of the control of the co	5. Number		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Ti Amo Unde Secu	tle and punt of erlying trities r. 3 and	Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownersh Form of Derivativ Security: Direct (D or Indirec	Ownersh (Instr. 4)	
							]	Date	Eisable E	xpiratio	1	Amount or Number				

#### **Reporting Owners**

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
ROSENWALD LINDSAY A MD 2 GANSEVOORT STREET, 9TH FLOOR NEW YORK, NY 10014	X					

# **Signatures**

/s/ James F. Oliviero, Attorney-in-Fact	06/11/2021
**Signature of Reporting Person	Date

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The 16,502 shares of restricted Common Stock will vest on June 10, 2024, subject to Dr. Rosenwald's continued service on the board on such date
- (2) Includes restricted shares of Common Stock which vest over various time periods, subject to Dr. Rosenwald's continued service on the board.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.